– USA, MA – Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it appointed Mary Ann Gray, Ph.D., to its Board of Directors. Dr. Gray has more than three decades of biotechnology and healthcare experience, with a track record of successfully guiding high-potential companies evolve to their next stage of growth. She will serve as a member of both Sarepta’s Compensation and Nominating and Corporate Governance Committees.
“We are very pleased to welcome Dr. Gray to Sarepta’s Board of Directors. Mary Ann is deeply tenured in providing governance and leadership for public companies as a director. With her impressive experience, coupled with her scientific and financial acumen, Dr. Gray will make an immediate contribution to Sarepta, as we accelerate our aspiration to become one of the most meaningful precision genetic medicine companies in the world by profoundly improving the lives of patients suffering from rare neuromuscular diseases and other rare diseases,” said M. Kathleen Behrens, Ph.D., Chairperson of Sarepta’s Board of Directors.
About Dr Gray
Dr. Gray has a distinguished scientific background, completing pharmacology research in tumor biology, including the impact of therapeutics on cardiac membranes. With an early career as a scientist focused on new drug development, she subsequently worked in equities research before becoming a senior analyst and portfolio manager. The combination of scientific and financial expertise provides unique insights for board leadership. She most recently served on the boards of Senomyx, and Juniper Pharmaceuticals, both companies were recently acquired; TetraLogic, a publicly-held clinical-stage biopharmaceutical company focused on oncology and infectious diseases, Dyax Corp., a rare disease company acquired by Shire in 2016; and ACADIA Pharmaceuticals, focused on commercialization of CNS therapies. She is President of Gray Strategic Advisors, LLC, a biotechnology strategic planning and advisory firm.
Dr. Gray holds a Bachelor of Science degree from University of South Carolina, a Ph.D. in pharmacology from the University of Vermont, and completed her post-doctoral work at Northwestern University Medical School and at the Yale University School of Medicine.
“Having watched Sarepta’s strategic transformation over the past 18 months as an outside observer, the company’s progress has been tremendous. And yet, even with such profound progress, it is clear that Sarepta has only begun to tap its potential. I’m excited to join Sarepta’s board and play a role at such a pivotal point in its journey,” said Dr. Gray.
About Sarepta Therapeutics
Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in Limb-girdle muscular dystrophy (LGMD), Charcot-Marie-Tooth (CMT) and CNS-related disorders, totaling over 20 therapies in various stages of development. The Company’s programs span across several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta intends to be one of the most meaningful precision genetic medicine company in the world, profoundly improving the lives of patients suffering from rare neuromuscular diseases and other rare diseases.
For more information : https://www.sarepta.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.